Latest period
$4.19M
YoY change
+6.3%
5Y CAGR
—
Peak year (2025)
$8.11M
Latest annual
$8.11M
Stock-Based Compensation history chart for Alto Neuroscience (ANRO) from 2021 to 2025
Latest: $8.11M
Stock-Based Compensation growth chart for Alto Neuroscience (ANRO) from 2021 to 2025
Latest: +6.3%
Stock-Based Compensation history table for Alto Neuroscience (ANRO) from 2021 to 2025
| 2025 | $8.11M | +6.3% | +$477.00K | ||
| 2024 | $7.63M | +164.0% | +$4.74M | ||
| 2023 | $2.89M | +64.0% | +$1.13M | ||
| 2022 | $1.76M | +676.7% | +$1.54M | ||
| 2021 | $227.00K | — | — |
- 2025$8.11M+6.3%
- 2024$7.63M+164.0%
- 2023$2.89M+64.0%
- 2022$1.76M+676.7%
- 2021$227.00K—
Stock-Based Compensation values are taken from Alto Neuroscience's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Alto Neuroscience (ANRO)
Stock-Based Compensation for Alto Neuroscience (ANRO): headline value $4.19M · YoY +6.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual stock-based compensation for Alto Neuroscience (ANRO) came in at $8.11M – grew 6.3% year-over-year.
$8.11M stands as the all-time-high annual stock-based compensation, posted in 2025, against a low of $227.00K during 2021.
Alto Neuroscience Stock-Based Compensation by Year
Alto Neuroscience Stock-Based Compensation 2025: $8.11M
In 2025, Alto Neuroscience reported stock-based compensation of $8.11M, grew 6.3% from 2024. This figure represents the highest annual value in the available history.
Alto Neuroscience Stock-Based Compensation 2024: $7.63M
Alto Neuroscience stock-based compensation in 2024 was $7.63M, surged 164.0% from 2023.
Alto Neuroscience Stock-Based Compensation 2023: $2.89M
2023's stock-based compensation for Alto Neuroscience came in at $2.89M, surged 64.0% from 2022.
Alto Neuroscience Stock-Based Compensation 2022: $1.76M
Alto Neuroscience posted stock-based compensation of $1.76M in 2022, surged 676.7% from 2021.
Alto Neuroscience Stock-Based Compensation 2021: $227.00K
Alto Neuroscience stock-based compensation in 2021 was $227.00K.
See more financial history for Alto Neuroscience (ANRO).
Sector peers by Stock-Based Compensation
Healthcare peers of Alto Neuroscience (ANRO), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Alto Neuroscience (ANRO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation